RA Capital Management 13F holdings, Q3 2019
Holdings as of September 30, 2019 · filings on SEC EDGAR · latest filing →
RA Capital Management disclosed 32 US equity positions worth $1.7bn in its Q3 2019 13F filing. The largest position was ASND at 23.7% of the reported book, followed by WVE and SYNTHORX INC. Against the Q2 2019 filing, it opened 9 new positions, added to 4 and reduced 5 among the top 32 holdings.
What did RA Capital Management own in Q3 2019? Top 32 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q2 2019 |
|---|---|---|---|---|---|---|---|
| 1 | ASND ASCENDIS PHARMA A S | Healthcare | 23.7% | $398.0m | 4,132,442 | 0% | held |
| 2 | WVE WAVE LIFE SCIENCES LTD | Healthcare | 9.5% | $159.6m | 7,775,207 | 0% | held |
| 3 | SYNTHORX INC | 9.4% | $158.2m | 9,724,598 | 0% | held | |
| 4 | RA PHARMACEUTICALS INC | 6.8% | $114.9m | 4,858,260 | 0% | held | |
| 5 | ZOGENIX INC | 5.4% | $90.5m | 2,260,751 | -39% | reduced | |
| 6 | EIDOS THERAPEUTICS INC | 4.6% | $77.8m | 2,162,671 | 0% | held | |
| 7 | RYTM RHYTHM PHARMACEUTICALS INC | Healthcare | 4.4% | $73.9m | 3,422,312 | 82% | added |
| 8 | SATSUMA PHARMACEUTICALS INC | 4.2% | $70.3m | 4,681,858 | – | new | |
| 9 | ORCHARD THERAPEUTICS PLC | 3.7% | $62.1m | 5,224,475 | 2% | added | |
| 10 | SLDB SOLID BIOSCIENCES INC | 2.8% | $47.3m | 4,571,164 | 70% | added | |
| 11 | RETROPHIN INC | 2.8% | $46.2m | 3,987,560 | – | new | |
| 12 | PREVAIL THERAPEUTICS INC | 2.5% | $41.3m | 3,363,605 | 23% | added | |
| 13 | TGTX TG THERAPEUTICS INC | Healthcare | 2.3% | $38.6m | 6,880,323 | 0% | held |
| 14 | ARVN ARVINAS INC | Healthcare | 2.1% | $35.8m | 1,663,512 | -1% | reduced |
| 15 | DICERNA PHARMACEUTICALS INC | 2.1% | $35.3m | 2,456,669 | 0% | held | |
| 16 | MYOVANT SCIENCES LTD | 1.9% | $32.1m | 6,166,875 | -6% | reduced | |
| 17 | CRINETICS PHARMACEUTICALS INC | 1.7% | $28.2m | 1,875,209 | 0% | held | |
| 18 | STOK STOKE THERAPEUTICS INC | Healthcare | 1.4% | $24.1m | 1,119,963 | 0% | held |
| 19 | SCPHARMACEUTICALS INC | 1.1% | $19.1m | 3,247,005 | 0% | held | |
| 20 | KALA PHARMACEUTICALS INC | 1.0% | $17.3m | 4,537,478 | 0% | held | |
| 21 | DTIL PRECISION BIOSCIENCES INC | 0.9% | $15.5m | 1,842,366 | 0% | held | |
| 22 | KOD KODIAK SCIENCES INC | Healthcare | 0.9% | $14.7m | 1,025,165 | – | new |
| 23 | ALEC ALECTOR INC | Healthcare | 0.9% | $14.4m | 1,000,000 | 0% | held |
| 24 | AXSM AXSOME THERAPEUTICS INC | Healthcare | 0.8% | $13.4m | 664,385 | -50% | reduced |
| 25 | PORTOLA PHARMACEUTICALS INC | 0.7% | $11.5m | 429,399 | – | new | |
| 26 | DVAX DYNAVAX TECHNOLOGIES CORP | 0.5% | $8.5m | 2,365,912 | – | new | |
| 27 | IGM BIOSCIENCES INC | 0.5% | $8.3m | 466,368 | – | new | |
| 28 | XFOR X4 PHARMACEUTICALS INC | 0.4% | $6.1m | 478,107 | -44% | reduced | |
| 29 | ODONATE THERAPEUTICS INC | 0.3% | $5.2m | 200,000 | 0% | held | |
| 30 | CHIMERIX INC | 0.2% | $4.2m | 1,782,202 | – | new | |
| 31 | ESSA PHARMA INC | 0.2% | $3.4m | 1,000,000 | – | new | |
| 32 | SENS SENSEONICS HLDGS INC | Healthcare | 0.2% | $2.7m | 2,727,273 | – | new |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.